SFE Investment Counsel Has $1.50 Million Position in Pfizer, Inc. (PFE)

SFE Investment Counsel decreased its position in shares of Pfizer, Inc. (NYSE:PFE) by 12.7% during the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 44,631 shares of the biopharmaceutical company’s stock after selling 6,484 shares during the quarter. SFE Investment Counsel’s holdings in Pfizer were worth $1,499,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Fisher Asset Management LLC lifted its stake in shares of Pfizer by 3.9% during the 2nd quarter. Fisher Asset Management LLC now owns 34,035,362 shares of the biopharmaceutical company’s stock valued at $1,143,248,000 after buying an additional 1,275,832 shares in the last quarter. Schwab Charles Investment Management Inc. increased its holdings in Pfizer by 6.4% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 33,274,658 shares of the biopharmaceutical company’s stock valued at $1,117,696,000 after acquiring an additional 2,013,835 shares during the last quarter. Macquarie Group Ltd. increased its holdings in Pfizer by 0.9% in the 1st quarter. Macquarie Group Ltd. now owns 24,683,746 shares of the biopharmaceutical company’s stock valued at $844,431,000 after acquiring an additional 228,405 shares during the last quarter. Boston Partners increased its holdings in Pfizer by 7.3% in the 1st quarter. Boston Partners now owns 24,263,989 shares of the biopharmaceutical company’s stock valued at $830,071,000 after acquiring an additional 1,649,801 shares during the last quarter. Finally, Bank of Montreal Can increased its holdings in Pfizer by 1.2% in the 2nd quarter. Bank of Montreal Can now owns 18,534,159 shares of the biopharmaceutical company’s stock valued at $622,562,000 after acquiring an additional 227,682 shares during the last quarter. Institutional investors own 69.36% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This report was published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this report on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The original version of this report can be read at https://stocknewstimes.com/2017/11/19/sfe-investment-counsel-has-1-50-million-position-in-pfizer-inc-pfe.html.

In other Pfizer news, insider Alexander R. Mackenzie sold 7,350 shares of the business’s stock in a transaction dated Thursday, August 31st. The shares were sold at an average price of $34.00, for a total value of $249,900.00. Following the completion of the sale, the insider now directly owns 132,124 shares of the company’s stock, valued at approximately $4,492,216. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Laurie J. Olson sold 8,064 shares of the business’s stock in a transaction dated Monday, August 21st. The shares were sold at an average price of $32.70, for a total transaction of $263,692.80. Following the completion of the sale, the insider now directly owns 74,506 shares of the company’s stock, valued at $2,436,346.20. The disclosure for this sale can be found here. Insiders have sold a total of 374,621 shares of company stock worth $12,796,098 over the last quarter. 0.06% of the stock is currently owned by insiders.

PFE has been the topic of a number of research reports. BMO Capital Markets reiterated a “buy” rating and issued a $37.00 price target on shares of Pfizer in a report on Wednesday, September 6th. UBS AG reiterated a “buy” rating and issued a $38.00 price target on shares of Pfizer in a report on Monday, July 31st. Cowen and Company set a $43.00 price target on shares of Pfizer and gave the company a “buy” rating in a report on Monday, August 14th. Sanford C. Bernstein set a $39.00 price target on shares of Pfizer and gave the company a “buy” rating in a report on Tuesday, September 19th. Finally, Zacks Investment Research upgraded shares of Pfizer from a “hold” rating to a “buy” rating and set a $40.00 price target on the stock in a report on Tuesday, October 3rd. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and twelve have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $38.48.

Pfizer, Inc. (NYSE PFE) opened at $35.37 on Friday. The company has a market cap of $211,960.00, a PE ratio of 14.15, a P/E/G ratio of 2.50 and a beta of 1.01. Pfizer, Inc. has a fifty-two week low of $30.51 and a fifty-two week high of $36.78. The company has a current ratio of 1.43, a quick ratio of 1.15 and a debt-to-equity ratio of 0.56.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 EPS for the quarter, beating the consensus estimate of $0.65 by $0.02. The company had revenue of $13.17 billion for the quarter, compared to the consensus estimate of $13.17 billion. Pfizer had a net margin of 18.69% and a return on equity of 25.41%. The firm’s revenue was up .9% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.61 EPS. equities analysts predict that Pfizer, Inc. will post 2.6 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Friday, December 1st. Investors of record on Friday, November 10th will be issued a dividend of $0.32 per share. The ex-dividend date is Thursday, November 9th. This represents a $1.28 annualized dividend and a yield of 3.62%. Pfizer’s payout ratio is 78.53%.

Pfizer Company Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer, Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply